Article citationsMore>>

Muto, I., Koga, H., Doi, R., Katayama, E., Nakama, K. and Nakama, T. (2022) Efficacy of Nivolumab and Ipilimumab Combined Therapy as a First-Line Therapy for Patients with Advanced Melanoma and the Urgent Need for an Effective Second-Line Therapy for Patients with Wild-Type BRAF in Japan: A Single Center Retrospective Study. The Kurume Medical Journal, 69, 75-80.
https://doi.org/10.2739/kurumemedj.ms6912008

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top